Thomson Reuters analysts have disclosed 10 deals – five biopharma licensing and five M&A deals concluded in 2014 – as candidates for the Breakthrough Alliance Awards, with voting now open and the winner to be announced at this year's Allicense meeting in San Francisco. more »
Researchers at the Dana-Farber Cancer Institute have developed a biomarker that could be broadly useful to test the effectiveness of many different cancer drugs in many different tumor types. more »
While patient engagement is firmly at the epicenter for health care initiatives and research efforts designed to speed the development of new cures, the American Medical Association (AMA) is reminding lawmakers that the physician voice also needs to be heard from ground zero. more »
- Malin eyes $360M Dublin IPO, as Cardio3, Quantum Genomics complete new share issues
- Nominees announced for Allicense Breakthrough Deal Awards
- AHRQ's RoPR off & running, but building awareness is critical
- HIV not the only important virus at CROI conference
- Chiasma prepping solo U.S. oral octreotide plan with $70M series E
- Patent filings up in China: What does that mean for the biopharma sector?
- China sees more than 20,000 pharma patents filed in 2013
- GPCR Consortium lands Novo Nordisk, Merck
- Cipla's challenge of Novartis' patent for COPD drug tests India's manufacturing law
- Common heart drug interactions traced to vitamin K: study
Thomson Reuters analysts have disclosed 10 deals – five biopharma licensing and five M&A deals concluded in 2014 – as candidates for the Breakthrough Alliance Awards, with voting now open and the winner to be announced at this year's Allicense meeting in San Francisco.
Antioxidants seem to be on a Bill Cosby-like downward spiral from wholesomeness to villainy.
The newest accusations can be found in the Feb. 9, 2015, issue of Cancer Cell, where scientists reported that antioxidants drove both the initiation and the progression of tumors, and that blocking antioxidant pathways could destroy tumor cells.
Because they scavenge free radicals, which induce DNA damage as well as other damage in cells, antioxidants were once thought to protect against cancer.
That idea, however, has not held up to scientific scrutiny.READ MORE »
- HIV not the only important virus at CROI conference »
- Export inhibitors ride SINE wave into neurodegeneration »
- Nanotechnology approaches target atherosclerotic plaques »
- Common heart drug interactions traced to vitamin K: study »
- Potent breast cancer candidate targets stem, bulk tumor cells »
- Vaccines can help fight drug resistance »
- Engineered insulin knows when it's needed »
- Brain tissue growth has research, development implications, study says »
- Hepatitis-liver cancer connection may yield tailored therapies »
- Patient engagement as important as the dataFebruary 20, 2015 | 5:50 PM | Posted by: Mari Serebrov
- Listening to the voice that mattersFebruary 04, 2015 | 3:35 PM | Posted by: Mari Serebrov
- States move forward as SEC lags on crowdfunding rulesJanuary 29, 2015 | 6:55 PM | Posted by: Michael Fitzhugh
- Old dogs and new tricks: The real-world consequences of excluding older adults from drug trialsDecember 10, 2014 | 8:14 PM | Posted by: Marie Powers
- Shoppers, start your engines: BioWorld’s 8th Annual Gift GuideDecember 01, 2014 | 6:12 PM | Posted by: Marie Powers
Partners in Focus
Cast Your Vote
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter